Humira Side Effects Lawsuit
Humira Side Effect Lawsuit
Our interpretation of research done by researchers at the Dallas-based Baylor Research Institute, leads us to believe in our opinion that Humira and other popular psoriasis drugs may put patients at an increased risk of heart attacks, stroke, and consequent death. The disclosure came a few months after the FDA issued a safety alert on 14 April 2011, linking the drug to a rare type of blood cancer in children and young adults. Humira, a TNF inhibitor, carries black box warning about fatal blood cancer and fungal infections.
The FDA permitted Illinois-based Abbott Laboratories to market Humira, brand name of adalimumab, in 2003 as a medication for severe rheumatoid arthritis. The drug, the first human monoclonal antibody, has been approved for use only in cases where other anti-rheumatic drugs are found to be insufficient. In 2007, the FDA allowed Humira to be used for the treatment of severely active Crohn's disease in adults. However, a number of studies have linked the drug to serious blood disorders, fungal and virus infections, liver injury, central nervous system problems leading to demyelinating disorders, cardiac failure, and tuberculosis. It suppresses TNF, a cytokine produced by white blood cells, which renders the immune system ineffective in the fight against new infections.
Humira Complaints and FDA Warnings
In 2005, the FDA disclosed that it had identified at least nine cases of neurological disorders caused by Humira within the first two years of its introduction. Two of these complaints were related to optic neuritis, inflammation of a nerve, resulting in pain and loss of function. According to a research report published in the Journal of the American Medical Association on May 17, 2006, Humira side effects put users at the risk of developing certain types of cancers.